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OBJECTIVE — Diabetes is associated with cognitive decline and dementia. However, the
relationshipbetweenthedegreeofhyperglycemiaandcognitivestatusremainsunclear.Thiswas
explored using baseline cognitive measures collected in the ongoing Memory in Diabetes
(MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
RESEARCH DESIGN AND METHODS — The relationship of A1C and fasting plasma
glucose (FPG) levels to performance on four cognitive tests was assessed, adjusting for age and
otherdeterminantsofcognitivestatus.ThetestsweretheDigitSymbolSubstitutionTest(DSST),
Mini Mental Status Examination (MMSE), Rey Auditory Verbal Learning Test, and Stroop Test.
RESULTS — A statistically signiﬁcant age-adjusted association was observed between the
A1C level and the score on all four cognitive tests. Speciﬁcally, a 1% higher A1C value was
associated with a signiﬁcant 1.75-point lower DSST score (95% CI 1.22 to 2.28; P 
0.0001), a 0.20-point lower MMSE score (0.11 to 0.28; P  0.0001), a 0.11-point lower
memoryscore(0.02to0.19,P0.0142),andaworsescore(i.e.,0.75smore)ontheStroop
Test (1.31–0.19, P  0.0094). The association between the DSST score and A1C persisted in all
multiple linear regression models. FPG was not associated with test performance.
CONCLUSIONS — Higher A1C levels are
associated with lower cognitive function in in-
dividuals with diabetes. The effect of glucose
lowering on cognitive function will be deter-
mined by the ongoing ACCORD-MIND trial.
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M
ild cognitive impairment repre-
sents an important phase on the
path from normal cognitive func-
tion to dementia. Affected individuals
have measurable deﬁcits in cognitive
function that may affect their ability to
master complex behaviors such as those
required for diabetes self-care (1). More-
over, because mild cognitive impairment
is more common than frank dementia, its
potential population health impact is
high.Forexample,theprevalenceofmild
cognitive impairment (i.e., predementia)
in the Cardiovascular Health Study was
19% in individuals aged 65 years and
29% in those aged 85 years.
Diabetesisassociatedwithpremature
mortality and is a risk factor for mild cog-
nitive impairment and both vascular de-
mentia (2–5) and Alzheimer’s disease
(2,6–8). Indeed, individuals with diabe-
tes are 1.5 times more likely to experi-
ence cognitive decline and frank
dementia than individuals without diabe-
tes (9). Precise reasons for the high mor-
bidity and mortality of diabetes remain
unknown; however, many studies have
demonstrated a link between many of the
consequences of diabetes and the degree
ofhyperglycemiaasmeasuredbytheA1C
or glucose level. Emerging evidence sug-
gests that a relationship between mea-
sures of short-term glucose control and
cognitive function also exists. For exam-
ple, in a cross-sectional analysis of 378
high-functioning individuals with diabe-
tes, higher A1C but not fasting plasma
glucose (FPG) levels were consistently as-
sociated with lower scores on two cogni-
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similar relationship with indexes of dysg-
lycemia (11,12); nevertheless, details re-
garding such a relationship remain
unclear.
TheActiontoControlCardiovascular
Risk in Diabetes (ACCORD) trial is a ran-
domized controlled trial of 10,251 indi-
viduals with established type 2 diabetes
who have a high risk for cardiovascular
disease (CVD) and whose screening A1C
was 7.5%. It will determine whether
therapeutic strategies targeting normo-
glycemia, normotension, and/or a normal
lipid proﬁle can reduce the rate of cardio-
vascular events more than standard ther-
apeutic approaches in individuals with
type 2 diabetes and either previous car-
diovascular events or additional cardio-
vascular risk factors. The Memory in
Diabetes (MIND) substudy of the AC-
CORD trial will determine whether these
interventions reduce cognitive decline
andstructuralbrainchangesinasubsetof
2,977 randomized individuals from sites
that participated in the MIND substudy.
Baseline data from the MIND substudy
provide a unique opportunity to assess
the cross-sectional relationship between
cognitive function and two different mea-
sures of glycemia: A1C and FPG.
RESEARCH DESIGN AND
METHODS— The design of the AC-
CORD-MIND trial was described else-
where (13). In brief, six of seven
ACCORD clinical networks in the U.S.
andCanadacomprising52of77sitespar-
ticipated in the ACCORD-MIND trial.
ACCORD participants aged 55
years who were ﬂuent in English or Span-
ishandwillingtoparticipateandwhohad
beenrandomizedintothemainACCORD
trial for 45 days were invited to partic-
ipateintheMINDsubstudy.Aftersigning
a consent form, eligible participants com-
pleted a 30-min battery of cognitive tests.
To ensure that participants were not hy-
poglycemic at the time of cognitive test-
ing, the tests were generally administered
after breakfast, and a capillary glucose
level was measured before testing. If the
result was 60 mg/dl (3.3 mmol/l), a
snackwasgiven,andthecapillaryglucose
value was measured again within 15 min;
if the repeat glucose level at that time was
still 60 mg/dl, the test was rebooked
for a different day. The battery was ad-
ministered and scored by certiﬁed tech-
nicians (either in English or Spanish),
and the data were entered centrally at
the ACCORD-MIND coordinating cen-
ter.Thestudyprotocolwasapprovedby
the research ethics board of each partic-
ipating center, and all participants pro-
vided written informed consent.
Measures of glycemic status
Baseline biochemical characteristics of
MIND participants were measured in the
central laboratory of the ACCORD main
trial. A1C was measured by a Tosah G7
automatedhighperformanceliquidchro-
matograph (in a laboratory with National
Glycohemoglobin Standardization Pro-
gramlevelIcertiﬁcationfortraceabilityto
the Diabetes Control and Complications
Trialreference);FPGwasmeasuredenzy-
maticallyonanHitachi917autoanalyzer.
Cognitive testing
Cognitive tests that measured perfor-
mance in speciﬁc domains of interest
were chosen because they were standard-
ized, widely used, had well-established
norms, and could be administered by
nonneuropsychologists. Cognitive train-
ing session and certiﬁcation of MIND
technicianswereconductedbyMINDco-
ordinating center data quality assurance
staff who were trained and supervised by
MIND investigators, as described previ-
ously (14).
Recertiﬁcation of test performance
was repeated 6 months after the initial
certiﬁcation and annually thereafter.
Thus, a planned review of the test admin-
istrators’ performance, which included a
review of the test session recorded via au-
diotape and examination of actual test
materials and scores, provided ongoing
quality assurance of the cognitive data.
Cognitive test administrators were pro-
vided written feedback on their perfor-
mance and were retrained as needed.
Because of the signiﬁcant number of
Spanish-speaking participants, validated
translationswereusedfortheMiniMental
Status Examination (MMSE) and Rey Au-
ditory Verbal Learning Test (RAVLT)
(15). Veriﬁed Spanish versions were cre-
ated for the other tests by the Columbia
University Hispanic Research and Re-
cruitment Center team through transla-
tion and back-translation.
The tests have been described previ-
ously(13).Inbrief,theDigitSymbolSub-
stitution Test (DSST) is a subtest of the
Wechsler Adult Intelligence Scale (3rd
edition), which assesses a wide array of
cognitive domains, most prominently vi-
sual motor speed, capacity for learning,
sustained attention, and working mem-
ory. It has been used extensively to mea-
sure cognitive function in cognitively
intact individuals, and its score is well
correlated with measures of physical
function and future cognitive decline
(16). The range of scores is 0 to 133,
with increasing scores indicating better
performance.
The MMSE is a screening tool for de-
tecting changes in cognitive skills (17). It
can also identify changes in cognitive
function for elderly individuals without
dementia and may identify individuals in
the prodromal phase of dementia. The
range of scores is 0 to 30, with increasing
scores indicating better performance.
The RAVLT assesses the ability to
memorize and to retrieve words (verbal
memory). The RAVLT has been used ex-
tensively in epidemiological research and
has been found to be sensitive to neuro-
logical impairment in a wide variety of
patients.
The Stroop Test evaluates the ability
to view complex visual stimuli and to re-
spond to one stimulus dimension while
suppressing the response to another di-
mension, an “executive” skill largely at-
tributed to frontal lobe function.
Measures of confounding variables
and covariates
We adjusted the analyses for several fac-
tors that may confound the association of
the glycemic status measures and cogni-
tive function, including 1) prevalent
CVD, deﬁned as a history of myocardial
infarction, angina with ischemic changes
on a graded exercise test or positive
imaging, previous coronary revascular-
izationprocedures,orstroke;2)hyperlip-
idemia, deﬁned as use of any lipid-
lowering agent or an untreated LDL
cholesterol level 130 mg/dl (3.38
mmol/l); 3) hypertension, deﬁned as ei-
ther a history of hypertension or use of
any antihypertensive agents; 4) alcohol
consumption, deﬁned as more than three
drinks per week; 5) neuropathy, deﬁned
aseitherahistoryofneuropathyorabsent
ankle reﬂexes or vibration sense for either
foot; 6) education, divided into three cat-
egories: no high school education, high
school education only, or college educa-
tion or more; and 7) depression, deﬁned
as either a history of depression or a score
of 10 or higher on the Physicians Health
Questionnaire (PHQ) 9, a depressive
symptoms screening instrument. Other
biochemical covariates measured in the
central ACCORD laboratory included
urine albumin, measured by the Dade Be-
hring reagent on a Behring nephelometer
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RochereagentonaHitachi917chemistry
autoanalyzer; and lipids, measured on a
Hitachi 917 autoanalyzer using meth-
ods standardized to the Centers for Dis-
ease Control and Prevention reference
methods.
Statistical analysis
The relationships between each of the
four measures of cognitive status (i.e., the
dependent variables), A1C, FPG, and
the confounding and covarying variables
described above were assessed with age-
adjusted linear regression using the raw
scores. Age adjustment was used because
age may confound the relationship be-
tween dysglycemia and cognitive func-
tion.
Multiplelinearregressionwasusedto
estimatetheindependentrelationshipbe-
tween either A1C or FPG and each of the
cognitivemeasuresaftercontrollingfor1)
age, sex, education, and depression
(model 1); 2) model 1 variables plus dia-
betesduration(model2);3)model1vari-
ables plus diabetes duration, race, and
language (model 3); 4) model 1 variables
plusahistoryofCVD(model4);5)model
1 variables plus stroke (model 5); and 6)
model 1 variables plus all of the indepen-
dent variables assessed in the simple lin-
ear regressions in Table 2 (model 6). For
categorical independent variables coded
as 0 or 1 indicator variables (e.g., hyper-
tension), the -coefﬁcient represents the
difference in predicted scores between
those with and without the variable. For
continuous independent variables (e.g.,
A1C),the-coefﬁcientrepresentsthedif-
ference in predicted scores for every
1-unitdifference(e.g.,1%forA1C)inthe
independent variable. The calculated R
2
foreachmodelindicatesthepercentageof
variability in cognitive test score results
explained by the model.
RESULTS— As noted in Table 1, the
2,977 trial participants had mean age of
62.5 years, mean A1C of 8.3%, and mean
FPGof175.5mg/dl(9.75mmol/l).Atotal
of 1,388 (47%) were women, 718 (24%)
reported previous CVD that was not
stroke-related, 151 (5%) reported a pre-
vious stroke, and 2,578 (87%) reported
previous hypertension; 392 (13%) did
not complete high school and 980 (33%)
had either a history of depression or a
PHQ 9 score consistent with some de-
pression. These baseline characteristics
are similar to those reported for the over-
all ACCORD trial (18).
Relationship between measures of
glycemia and cognitive test scores
A1C. A statistically signiﬁcant age-
adjusted association was observed be-
tween the A1C level and the score on all
fourcognitivetests(Table2).Speciﬁcally,
a 1% higher A1C value was associated
with a 1.75-point lower DSST score (95%
CI 1.22 to 2.28; P  0.0001), a 0.20-
point lower MMSE score (95% CI 0.11
to 0.28; P  0.0001), a 0.11-point
lower memory score (95% CI 0.02 to
0.19, P  0.0142), and a worse score
(i.e., 0.75 s more) on the Stroop Test
(95% CI 1.31–0.19, P  0.0094).
As noted in Fig. 1, a signiﬁcant rela-
tionship between a higher A1C and lower
DSST score persisted in all six models,
with the weakest relationship noted after
accounting for race and language. A sim-
ilar signiﬁcant relationship was noted for
theadjustedMMSEandmemoryscoresin
someofthemodels;however,higherA1C
levels were not signiﬁcantly associated
with higher Stroop Test scores after ad-
justment for the variables in any model.
Thus, after adjustment for age, sex, edu-
cation, and depression score (model 1,
Fig. 1A–C), a 1% higher A1C was associ-
ated with a 1.43-point (95% CI 0.94 to
Table 1—Baseline characteristics of ACCORD-MIND participants
Variable Result
n 2,977
Female sex (%) 1,388 (47)
Age (years) 62.5  5.8
Diabetes duration (years) 10.4  7.3
Mean BMI (kg/m
2) 33.0  5.4
Mean urine albumin-to-creatinine ratio 0.092  0.404
Previous cardiovascular disease (%)* 869 (29)
Stroke (%) 151 (5)
Nonstroke (%) 718 (24)
Hyperlipidemia (%)† 2,426 (82)
Previous hypertension or use of blood pressure drugs (%) 2,578 (87)
Current smoker (%) 352 (12)
3 drinks/week (%) 232 (8)
Education
Not a high school graduate (%) 392 (13)
Just high school (%) 769 (26)
Some college or technical school (%) 1,027 (35)
College graduate or more (%) 789 (27)
Ethnicity
Hispanic (%) 213 (7)
Non-Hispanic white (%) 2,074 (70)
African American/African Canadian (%) 478 (16)
Asian (%) 67 (2)
American Indian/Alaska Native (%) 65 (2)
Other (%) 80 (2.6)
Vitrectomy (%) 15 (0.5)
Neuropathy (%)‡ 1,472 (50)
Past or current depression or PHQ 9 score 10 (%) 980 (33)
Living alone (%) 654 (22)
Cognitive testing in Spanish 63  2.1
DSST score 53 (42–63)
MMSE score 28 (26–29)
Memory score 7.4 (5.7–9.3)
Stroop Test score (s) 29 (21–38)
A1C (%) 8.3  1.1
FPG (mg/dl) 175.5  55
Data are means  SD, n (%), or median (25th–75th percentile). The range of scores for the ACCORD
participants is DSST 2–97, MMSE 12–30, memory 0.9–14.5, and Stroop 10 to 171. *Myocardial infarc-
tion, angina with ischemic changes on graded exercise test or positive imaging, coronary revascularization
procedures,orstroke.†Takinglipid-loweringmedicationoranuntreatedLDLcholesterollevel130mg/dl
(3.38 mmol/l). ‡History of neuropathy or absent ankle reﬂexes or vibration perception at great toe for either
foot.
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0.14-point (0.06 to 0.22; P  0.001)
lower MMSE score, and a 0.09-point
(0.01 to 0.17; P  0.02) lower mem-
ory score.
Figure 1 also shows R
2 values for the
adjusted models both with and without
theA1Cterm.Thesmalldifferencesinthe
two R
2 values for each model where A1C
is associated with the cognitive test indi-
cates that A1C levels, although statisti-
cally signiﬁcant, only explain a small
additional amount of the variability in
cognitive test scores compared with that
explained by the model excluding the
A1C term.
FPG. Unlike for A1C, no signiﬁcant re-
lationship between the FPG and any of
the cognitive tests was observed in the
age-adjusted or multiple regression anal-
yses (Table 2).
CONCLUSIONS — This analysis of
3,000 individuals with established type
2 diabetes demonstrates a clear age-
adjusted inverse relationship between
cognitive function and the degree of
chronic hyperglycemia as measured by
theA1Clevel.Theobservedeffectofa1%
change in A1C on tests scores is clearly
small; nevertheless, such an effect may be
clinically important. For example, in the
same sample every 1-year increase in age
was associated with a 0.7-point decrease
in DSST score (data not shown). There-
fore, the 1- to 1.5-point difference in
DSST per 1% higher A1C corresponds to
an age difference of up to 2 years. More-
over, several recent studies demonstrated
the clinical importance of this difference.
Thus, a cross-sectional study in older
healthy individuals reported that a
3-point difference in DSST score was as-
sociated with lower scores on physical
performance tests (16), and in a 3-year
follow-up study a 1-point difference in
baseline DSST score signiﬁcantly in-
creased the risk for the development of
Alzheimer’s disease among individuals
with minimal cognitive impairment (19).
Finally, during a mean follow-up of 3.3
years, a 1-point difference in baseline
DSST score was associated with a 3% in-
crease in the risk for dementia in commu-
nity dwellers aged 70 years (20).
The relationship between the A1C
level and cognition was attenuated after
adjustment for other factors associated
with cognitive function in some of the
models but remained signiﬁcant for the
DSST score in every adjusted model.
Theseﬁndingssuggestthatmuch,butnot
all, of the relationship between A1C and
cognitive function may be explained by
risk factors other than A1C. Thus, the
small increment in the R
2 value (Fig. 1)
attributabletoadditionoftheA1Ctermto
the multivariable models (which reﬂects
the degree to which the model accounts
for the cognitive test score) suggests that
A1Cisnotthecrucialdeterminantofcog-
nitive score after consideration of these
other factors and particularly those re-
lated to ethnicity/language. However,
these other factors are mostly not modiﬁ-
able, whereas A1C levels can be changed
with therapy. This evidence for a small
additional signiﬁcant effect of A1C on
cognitive test scores therefore supports
(but clearly does not prove) the hypothe-
sisthatloweringA1Cmayhaveanimpact
on these scores.
Takentogether,theseanalysesextend
previous reports of a link between cogni-
tive decline and diabetes and are consis-
tent with the hypothesis of a progressive
relationship between the degree of
chronichyperglycemiaandcognitivedys-
function.
The fact that optimal diabetes care re-
quiresaffectedpatientstomaketherapeu-
tic decisions based on information that
they collect and process highlights the
clinical signiﬁcance of this ﬁnding. Fi-
nally, the absence of a clear relationship
between FPG and these tests may be due
to the fact that FPG is not as reliable as
A1C as a measure of the underlying
chronic glycemic status.
A number of possibilities may ex-
plain these ﬁndings. Because higher
glucose levels are associated with a
higher prevalence of cardiovascular risk
factors and CVD, the relationship with
cognitive dysfunction may be mediated
through CVD. The fact that this rela-
tionship is not attenuated by adjusting
for CVD reduces but does not com-
pletely eliminate this possibility. It is
also possible that chronic exposure of
the brain to high levels of glucose may
accelerate cognitive decline. Indeed,
postmortem studies of senile plaques
from the brains of individuals with Alz-
heimer’s disease demonstrate metabolic
Table 2—-coefﬁcients for the age-adjusted relationship between cognitive test scores, gly-
cemic status, and other variables: ACCORD-MIND
Variable DSST MMSE
Memory
score Stroop
Female sex 1.79 0.27 1.30§ 0.41
Diabetes duration (years) 0.26§ 0.14 0.01 0.01
CVD* 1.98 0.12 0.48§ 1.43
Stroke 8.18§ 0.69 0.86§ 4.53
Nonstroke CVD 0.08 0.32 0.31 0.40
Hyperlipidemia† 1.95 0.02 0.12 1.22
Hypertension or blood pressure drugs 1.78 0.11 0.14 0.37
Current smoker 2.75 0.29 0.46 0.38
3 drinks/week 4.80§ 0.76§ 0.01 2.81
Education
 high school 22.51§ 3.24§ 1.89§ 12.30§
High school 10.63§ 1.4§ 0.89§ 6.63§
Some college 5.2§ 0.6§ 0.41 3.86§
Language 25.97§ 2.7§ 1.51§ 10.27§
Race (Nonwhite) 13.39§ 1.92§ 0.83§ 6.71§
Vitrectomy 7.78 0.49 0.50 7.11
Neuropathy‡ 1.84 0.41§ 0.17 0.82
Depression or PHQ 9 score 10 1.04 0.34 0.05 0.54
Living alone 0.21 0.07 0.27 1.19
BMI (kg/m
2) 0.20 0.04§ 0.04§ 0.04
Urine albumin-to-creatinine ratio 3.06§ 0.11 0.20 1.29
A1C (%) 1.75§ 0.20§ 0.11 0.75
Fasting plasma glucose (mmol/l) 0.0057 0.0006 0.00006 0.0055
*Myocardial infarction, angina with ischemic changes on graded exercise test or positive imaging, coronary
revascularization procedures, or stroke. †Taking lipid-lowering medication or an untreated LDL cholesterol
level 130 mg/dl (3.38 mmol/l).‡History of neuropathy or absent ankle reﬂexes or vibration perception at
great toe for either foot. §P  0.0001; P  0.05.
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perglycemia (21,22).
Athirdpossibilityisrelatedtothefact
that higher A1C levels imply insufﬁcient
action or effect of insulin due to insufﬁ-
cientsecretion,activity,orboth.Thereare
manyinsulinreceptorsinthebrain.Some
havearoleinglucosetransport,butmany
arethoughttohaveafunctionincognitive
processes. Several observations suggest
that cognitive decline is a consequence of
reduced insulin action in the brain. In in-
dividuals without diabetes, worse gluco-
regulation (as measured by a glucose
tolerance test) was associated with worse
outcomes on cognitive assessment, espe-
cially in elderly individuals. Individuals
with Alzheimer’s disease also have less ef-
ﬁcient glucoregulation than unaffected
individuals(23),andexposureofindivid-
uals with Alzheimer’s disease to a eugly-
cemic-hyperinsulinemic clamp improved
cognitive function, whereas exposure to a
euinsulinemic-hyperglycemic clamp had
no effect (23,24).
There are limitations to this study.
First, because the analyses were cross-
sectional, it is not possible to make any
temporal or causal inferences regarding
relationships. Second, cognitive tests
were administered to individuals of sev-
eral ethnic groups and in two languages,
thus increasing the variability of the mea-
surement. Third, the ACCORD trial ex-
cluded individuals whose most recent
A1Cwas7.5%or11%andthosewho
were deemed unable to participate in
their diabetes management; these results
may therefore not apply to individuals
with lower or higher A1C levels or signif-
icant cognitive impairment. Fourth, ex-
clusion of individuals with lower A1C
levels means that the relationship be-
tweenA1Candcognitionisstudiedovera
narrow range of A1C levels. This reduces
the ability to detect a relationship, and
thus the link between A1C and cognition
may have been underestimated. How-
ever, this large sample of individuals with
diabetes is well powered to study the as-
sociation of A1C levels and cognition.
Insummary,thiscross-sectionalanal-
ysisillustratesthatchronichyperglycemia
appears to be independently associated
with cognitive function in individuals
withdiabetes.Italsoraisesthehypothesis
that strategies to lower A1C levels or pre-
vent their rise may favorably affect cogni-
tive function. Such a hypothesis can only
be tested in prospective studies, such as
the ongoing ACCORD-MIND trial.
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APPENDIX
The Action to Control Cardiovascular
Risk in Diabetes-Memory in Diabetes
(ACCORD-MIND) Investigators are the
following. Executive Committee: Lenore J.
Launer,R.NickBryan,MikeE.Miller,Jeff
D. Williamson. Canadian Clinical Center
Network (CCN): McMaster University and
Hamilton Health Sciences, Hamilton,
ON, Canada: Hertzel Gerstein, MD, MSc;
Tali Cukierman-Yaffee, MD, MSc. West-
ern CCN: University of Washington, Seat-
tle, WA: Mark D. Sullivan, MD, PhD.
Minnesota-Iowa CCN: Berman Center for
Outcomes and Clinical Research, Minne-
apolis, MN: Anne Murray, MD, MSc.
Ohio-Michigan CCN: Case Western Re-
serveUniversity,Cleveland,OH:KarenR.
Horowitz, MD. Northeastern CCN: Co-
lumbia University College of Physicians
and Surgeons, New York, NY: Ronald M.
Lazar,PhD.SoutheasternCCN:WakeFor-
est University School of Medicine, Win-
ston-Salem, NC: Jingzhong Ding, MD,
PhD. Coordinating Center: Wake Forest
University School of Medicine, Winston-
Salem,NC:JeffD.Williamson,MD,MHS;
Laura H. Coker, PhD; Michael E. Miller,
PhD. MRI Quality Control: University of
Pennsylvania, Philadelphia, PA: R. Nick
Bryan, MD, PhD. Project Ofﬁce: National
Institute on Aging, National Institute of
Health, Bethesda, MD: Lenore J. Launer,
PhD.
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